Sermorelin: the GHRH fragment with an FDA past, a compounding pharmacy present, and a real anti-aging evidence base worth understanding.
Sermorelin is the first 29 amino acids of endogenous human growth hormone-releasing hormone (GHRH), the smallest GHRH fragment with full GHRH receptor agonist activity. It was FDA-approved in 1997 under the brand name Geref for treatment of GH deficiency in children, and was manufactured until 2008 when Serono discontinued the product for commercial (not safety) reasons. Since then, it has been available through compounding pharmacies and is one of the most studied GHRH analogs in both pediatric and adult populations.
- GHRH(1-29)-NH₂ — the minimal active fragment of endogenous GHRH. Acts at the pituitary GHRH receptor to stimulate GH synthesis and release.
- FDA-approved 1997 (pediatric GH deficiency); discontinued by Serono 2008 for commercial reasons, not safety. Currently available via compounding pharmacies.
- Unlike CJC-1295, sermorelin does not use a DAC (drug affinity complex) to extend half-life — it is a short-acting GHRH stimulant requiring more frequent administration for sustained GH elevation.
- Adult anti-aging off-label use: clinical evidence shows improvements in lean mass, fat mass, bone density, and quality-of-life measures in GH-deficient adults.
- Key difference from direct GH injection: sermorelin stimulates physiological pulsatile GH release, maintaining somatostatin feedback and avoiding supraphysiological GH exposure.
- Compounding pharmacy status: FDA has not placed sermorelin on the 503A prohibited list (unlike BPC-157), making it legally compoundable in the US.
Why the FDA history matters
Sermorelin occupies a unique position in the peptide landscape: it has actually been FDA-approved, which means it has passed Phase I–III clinical trials for safety, pharmacokinetics, and efficacy. The discontinuation by Serono in 2008 was a commercial decision — pediatric GH deficiency is a small market with increasing competition from recombinant GH, which offers a more convenient daily injection versus sermorelin's more complex administration requirements. The safety and efficacy profile established during the approval program remains valid.
This matters because the pharmacological characterization of sermorelin in humans is far more complete than for most research peptides. Published human data includes dose-response relationships, pharmacokinetics after IV and SC administration, GH pulse amplitude data across populations, and long-term safety data from the pediatric clinical program.
Mechanism: physiological GHRH receptor agonism
Sermorelin binds the pituitary GHRH receptor (GHRHR), a Gs-coupled GPCR. Receptor activation increases intracellular cAMP, which stimulates GH synthesis and the GH exocytotic machinery in pituitary somatotroph cells. The result is a GH pulse — a rapid surge of GH secretion that follows the normal physiological pulsatile pattern.
Because sermorelin stimulates GH through the normal physiological pathway (rather than injecting GH directly), somatostatin feedback is preserved. Somatostatin (SRIH) is the endogenous inhibitor of GH release — when GH levels rise, somatostatin tone increases to suppress further release. This feedback is bypassed by direct GH injection but not by GHRH stimulation, which is why GHRH analogs like sermorelin are argued to produce more "physiological" GH elevation patterns with less risk of supraphysiological exposure.
The adult anti-aging evidence
The most clinically relevant evidence for sermorelin in adults comes from off-label use studies in GH-deficient middle-aged individuals:
- Walker et al. (2004) published a placebo-controlled trial of nightly SC sermorelin in GH-deficient adults over 6 months, showing significant improvements in body composition (increased lean mass, decreased fat mass), bone density, and quality-of-life measures (PMID: 15213316).
- Nass et al. (2008) showed that low-dose SC sermorelin over 12 months in older adults with low IGF-1 increased IGF-1 to youthful levels while maintaining physiological GH pulse patterns (PMID: 18768619).
- Multiple compounding pharmacy-affiliated studies show favorable safety and body composition profiles in the 40–65 age range with nightly administration.
An important caveat: some of this adult evidence comes from GH-deficient populations where baseline GH is pathologically low. The effect size in individuals with normal-for-age GH levels is expected to be smaller.
Sermorelin vs. CJC-1295: the key differences
CJC-1295 (with DAC) extends GHRH activity by covalently binding serum albumin, dramatically extending half-life to ~8 days. Sermorelin has a short half-life (~10–12 min IV) requiring frequent administration.
| Parameter | Sermorelin | CJC-1295 (with DAC) |
|---|---|---|
| Half-life | ~10–12 min | ~7–8 days |
| Administration frequency | Daily (nightly preferred) | Weekly or biweekly |
| GH pulse pattern | Pulsatile (physiological) | Sustained elevation |
| Somatostatin feedback | Preserved | Partially bypassed (sustained) |
| FDA history | Approved (discontinued) | None |
| Compounding legal status (US) | Allowable | 503A restricted (with DAC) |